Form 8-K · Current Report · Filed 2025-09-10

Revolution Medicines Reports Positive Clinical Data for Daraxonrasib in Pancreatic Cancer Treatment

Revolution Medicines, Inc. reported updated clinical data for daraxonrasib, its RAS(ON) multi-selective inhibitor, showing positive safety, tolerability, and activity profiles in patients with RAS-mutant pancreatic ductal adenocarcinoma (PDAC). In the Phase 1 RMC-6236-001 study, daraxonrasib demonstrated an objective response rate (ORR) of 35% for patients with tumors harboring RAS G12X mutations and 29% for those with RAS G12X, G13X, or Q61X mutations. The median progression-free survival (PFS) was 8.5 months for RAS G12X mutations and 8.1 months for G12X, G13X, or Q61X mutations. Additionally, the Phase 1 RMC-GI-102 study showed promising initial data for the combination of daraxonrasib with gemcitabine and nab-paclitaxel in the first-line setting, with an ORR of 55%. The Company believes these results support the continued development of daraxonrasib in PDAC.